Research Papers

25 of 388 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Stricture dilation <i>via</i> balloon-assisted endoscopy in Crohn's disease: approach and intraprocedural outcomes with…
Halloran BP; Reeson M; Teshima C; Kroeker K; Huang V; Dieleman L; Holmes P; Baumgart DC; Wong K; Hoentjen F; Peerani F; Zepeda-Gomez S.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary tract cancer.
Ge P; Wu Y.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.
Anjie SI; Gecse KB; Ponsioen CY; Löwenberg M; D'Haens GR.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Management of chronic pancreatitis: recent advances and future prospects.
Han C; Lv YW; Hu LH.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel dis…
Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK.
Therap Adv Gastroenterol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.
Brunet-Mas E; Garcia-Sagué B; Vela E; Melcarne L; Llovet LP; Pontes C; García-Iglesias P; Puy A; Lario S; Ramirez-Lazaro MJ; Villoria A; Burisch J; Kaplan GG; Calvet X.
Therap Adv Gastroenterol (Unknown)
Published: 2024
4/6 Transparent
Registered Funding Declared
New genetic biomarkers predicting 5-aminosalicylate-induced adverse events in patients with inflammatory bowel diseases.
Park J; Park IS; Kim JH; Ji JH; Park SJ; Park JJ; Kim TI; Kim SW; Cheon JH.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and autoimmune phenomen…
Li M; Chen S; Li S; Lv T; Li B; Shan S; Li M; Zeng N; Wang Q; Kong Y; Ma H; Zhao X; Ou X; You H; Duan W; Jia J.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>KRAS</i> mutation res…
Béchade D; Palmieri LJ; Bonhomme B; Pernot S; Léna J; Fonck M; Pesqué S; Boillet G; Italiano A; Roseau G.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Treatment persistence and switching patterns of ABP 501 in European patients with inflammatory bowel disease.
Jin R; Kruppert S; Scholz F; Bardoulat I; Karzazi K; Kricorian G; O'Kelly JL; Reinisch W.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis tr…
Calafat M; Torres P; Tosca-Cuquerella J; Sánchez-Aldehuelo R; Rivero M; Iborra M; González-Vivo M; Vera I; de Castro L; Bujanda L; Barreiro-de Acosta M; González-Muñoza C; Calvet X; Benítez JM; Llorente-Barrio M; Surís G; Cañete F; Arias-García L; Monfort D; Castaño-García A; Garcia-Alonso FJ; Huguet JM; Marín-Jímenez I; Lorente R; Martín-Cardona A; Ferrer JÁ; Camo P; Gisbert JP; Pajares R; Gomollón F; Castro-Poceiro J; Morales-Alvarado J; Llaó J; Rodríguez A; Rodríguez C; Pérez-Galindo P; Navarro M; Jiménez-García N; Carrillo-Palau M; Blázquez-Gómez I; Sesé E; Almela P; Ramírez de la Piscina P; Taxonera C; Rodríguez-Lago I; Cabrinety L; Vela M; Mínguez M; Mesonero F; García MJ; Aguas M; Márquez L; Silva Porto M; Pineda JR; García-Etxebarría K; Bertoletti F; Brunet E; Mañosa M; Domènech E.
Therap Adv Gastroenterol (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Advancements in endoscopic management of small-bowel polyps in Peutz-Jeghers syndrome and familial adenomatous polyposi…
Funayama Y; Shinozaki S; Yano T; Yamamoto H.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Early infliximab trough levels in paediatric IBD patients predict sustained remission.
Bevers N; Aliu A; Wong DR; Winkens B; Vreugdenhil A; Pierik MJ; Derijks LJJ; van Rheenen PF.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Crossing barriers: the burden of inflammatory bowel disease across Western Europe.
Kumar A; Yassin N; Marley A; Bellato V; Foppa C; Pellino G; Myrelid P; Millan M; Gros B; Avellaneda N; Catalan-Serra I; El-Hussuna A; Cunha Neves JA; Roseira J; Cunha MF; Verstockt B; Bettenworth D; Mege D; Brookes MJ.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Burnout among European IBD specialists: a survey supported by ECCO.
Dávid A; Volosin M; Farkas K; Resál T; Keresztes C; Rafael B; Molnár T.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Prevalence and risk factors for early medical and surgical complications following an admission for acute severe ulcera…
Li A; Coote M; Thin L.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients.
Martins CA; de Azevedo MFC; Carlos AS; Damião AOMC; Sobrado Junior CW; Nahas SC; Queiroz NSF.
Therap Adv Gastroenterol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
Association between IL-6 and prognosis of gastric cancer: a retrospective study.
Liang P; Zhang Y; Jiang T; Jin T; Chen Z; Li Z; Chen Z; He F; Hu J; Yang K.
Therap Adv Gastroenterol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
IBD barriers across the continents - East Asia.
Mak JWY; Ho AHY; Ng SC.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Associations of sugar-sweetened beverages, artificially sweetened beverages, and natural juices with cardiovascular dis…
Dan L; Fu T; Sun Y; Ruan X; Lu S; Chen J; Wang X.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a c…
Zhu Y; Liu K; Zhu H; Wu H.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Optimal liver drainage rate for survival in patients with unresectable malignant hilar biliary obstruction using 3D-ima…
Morimoto K; Matsumoto K; Obata T; Oda T; Miyamoto K; Matsumi A; Terasawa H; Fujii Y; Yamazaki T; Horiguchi S; Tsutsumi K; Kato H; Otsuka M.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Clinical utility of colon capsule endoscopy: a moving target?
Jalayeri Nia G; Arasaradnam RP; Koulaouzidis A.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dos…
Koo HM; Jun YK; Choi Y; Shin CM; Park YS; Kim N; Lee DH; Shin YK; Yoon H.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The new normal: a review of the impact of COVID-19 on gastroenterology fellowship training.
Makhani S; Morales J; Whitson MJ.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared